IGHE and plasma cell myeloma: In vitro studies showed that arctigenin dose-dependently inhibited IgE synthesis in IgE-producing human myeloma U266 cells, and in vivo murine models supported these findings by exhibiting significant reductions in allergen-specific IgE levels.